Investigating Bone and Metabolic Outcomes in Postmenopausal Women: OASIS-3 Results
E. Michael Lewiecki, MD, discusses how menopause significantly impacts bone health through increased bone remodeling and loss, while exploring promising new neurokinin-targeted therapies like elinzanetant that may simultaneously treat vasomotor symptoms and provide skeletal benefits, as demonstrated in the OASIS-3 trial's subanalysis showing improved bone mineral density, reduced bone turnover markers, and favorable body composition changes compared with placebo.
EP. 1: Impact of Menopause on Bone Health and Fracture Risk
July 28th 2025An expert discusses how menopause triggers increased bone remodeling with imbalanced resorption exceeding formation, leading to progressive bone loss and potential osteoporosis that requires careful attention to optimize bone health.
EP. 2: Therapies for Vasomotor Symptoms and Their Effects on Bone Mineral Density
July 28th 2025An expert discusses how estrogen remains the most effective treatment for vasomotor symptoms while also benefiting bone density, though alternative treatments like paroxetine and fezolinetant lack bone health benefits.
